Open AccessRisk Factors for and Trends in Isoniazid Monoresistance at Diagnosis of Tuberculosis—United States, 1993-2016
Author(s) -
Shareen Iqbal,
Lori Armstrong,
J. Steve Kammerer,
Benedict I. Truman
Publication year - 2019
Publication title -
journal of public health management and practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.771
H-Index - 50
eISSN - 1550-5022
pISSN - 1078-4659
DOI - 10.1097/phh.0000000000001060
Subject(s) - ethambutol , pyrazinamide , isoniazid , tuberculosis , medicine , confidence interval , odds ratio , logistic regression , drug resistance , mycobacterium tuberculosis , demography , pediatrics , environmental health , pathology , biology , sociology , microbiology and biotechnology
Resistance to isoniazid (INH) only (monoresistance), with drug susceptibility to rifampin, pyrazinamide, and ethambutol at diagnosis of tuberculosis (TB) disease, can increase the length of treatment.